Protein-polysaccharide conjugate vaccines against Streptococcus pneumoniae promise to be an effective public health intervention for children, especially in an era of increasing antimicrobial resistance. To characterize the distribution of capsular types in Latin America, surveillance for invasive pneumococcal infection in children £5 years of age was done in six countries between February 1993 and April 1996. Fifty percent of 1,649 sterile-site isolates were from children with pneumonia, and 52% were isolated from blood. The 15 most common of the capsular types prevalent throughout the region accounted for 87.7% of all isolates. Overall, 24.9% of isolates had diminished susceptibility to penicillin: 16.7% had intermediate resistance and 8.3% had high-level resistance. Three customized vaccine formulas containing 7, 12, and 15 capsular types were found to have regional coverages of 72%, 85%, and 88%, respectively. This study emphasizes the need for local surveillance for invasive pneumococcal disease prior to the development and evaluation of proteinpolysaccharide conjugate vaccines for children.
Acute respiratory tract infection (ARI) accounts for ú4 milmined for the United States [9] and Europe [10] . Limited data from developing countries suggest that the capsular-type distrilion childhood deaths in the developing world each year [1] . Seventy percent of all ARI-related deaths are due to pneumobution of S. pneumoniae is different from that in the developed world [11, 12] . Determination of the regional pneumococcalnia, of which Streptococcus pneumoniae is the most frequent bacterial cause [2, 3] . There are few data describing the epidetype distribution and assessment of differences in type prevalence between countries are crucial antecedents to the developmiology of invasive S. pneumoniae infection in Latin America, although several studies [4 -6] confirm that the pathogen is the ment and use of any protein-polysaccharide conjugate vaccines in Latin America. most frequent bacterial cause of childhood pneumonia in this region.
To address this issue, the Pan American Health Organization, as part of the Sistema Regional de Vacunas (SIREVA) initiaThe burden of pneumococcal illness in developing countries and the global emergence of antibiotic-resistant S. pneumoniae tive, developed a network of national reference laboratories to conduct region-wide, prospective surveillance of invasive [7] make prevention by immunization an appealing control strategy. The currently available 23-valent polysaccharide vacpneumococcal infections in children in Latin America, with laboratory and epidemiological support provided by the Canacine, however, is poorly immunogenic in children õ2 years of age, who remain disproportionally affected by pneumococcal dian National Centre for Streptococcus (NCS; Edmonton, Alberta) and the Bureau of Infectious Diseases, Laboratory Centre disease. A new generation of protein-polysaccharide conjugate vaccines is being developed to address this problem [8] .
for Disease Control, Health Canada (Ottawa). The network's specific objective was to determine the relative prevalence of The optimal capsular-type composition for a protein-polysaccharide conjugate pneumococcal vaccine has been detercapsular types of S. pneumoniae causing invasive disease, particularly pneumonia, in children £5 years of age in Latin America.
tals were selected if they served a pediatric patient population and had clinicians and microbiologists willing to participate. Investigators attempted to select hospitals from different geographic regions within each country. Clinicians collected sterile-site specimens, including blood and cerebrospinal, pleural, peritoneal, or articular fluid, from patients £5 years of age who presented with meningitis, either sepsis or bacteremia without an infectious focus, arthritis, peritonitis, or signs fulfilling the World Health Organization's clinical criteria for pneumonia [13] . Patients were excluded from the study if they had been ill for ú15 days or if they had laryngeal stridor or croup. Nasopharyngeal swab specimens, bronchial aspirates, and specimens from bronchoalveolar la- pneumococci were isolated from more than one specimen type, only one was listed; blood was considered the primary source, followed by CSF.
duced by each for the other [17] . The vaccine formulas were Representatives from each national reference laboratory met Vac7, Vac12, and Vac15, containing the most frequently isoat the NCS before the study began to review laboratory methodlated types 7, 12, and 15, respectively. ology detailing standard procedures for the isolation and identiDifferences between countries in the age and presenting dification of S. pneumoniae [14] . Serotyping, according to the agnosis of patients were identified as factors that could conDanish nomenclature system, was done by Quellung reaction found type distribution. To address this, a stratified analysis with use of 12 pooled antisera [15] and selected factor sera with use of Mantel-Haenszel odds ratios and 95% confidence (Statens Seruminstitut, Copenhagen). Isolates that national refintervals was used to compare the proportion of subjects in erence laboratories were unable to type were sent to the NCS each country covered by the three products. Uruguay was used for evaluation. Isolates found to be nontypeable at the NCS as an internal standard for intercountry comparison because it were referred to the Statens Seruminstitut.
had the highest coverage with each of the vaccine formulas. All isolates were screened for reduced susceptibility to peniAny country with a proportion of coverage that did not differ cillin with use of a 1-mg oxacillin disk on Mueller-Hinton agar significantly from Uruguay's could be confident of having covsupplemented by 5% sheep blood. The MIC of penicillin was erage that approached this region-high level. determined by broth microdilution [16] . Susceptibility to penicillin was defined by an MIC of £0.06 mg/mL, intermediate susceptibility by an MIC of 0.12 -1.0 mg/mL, and high-level Results resistance by an MIC of §2.0 mg/mL. S. pneumoniae ATCC 49619 was included as a control strain for each testing batch.
Between February 1993 and April 1996, 1,649 isolates of S. pneumoniae were recovered from children in Argentina (n Å A laboratory quality-control program was established by the NCS, through which 10% of the isolates were sent to the NCS 424), Brazil (n Å 364), Colombia (n Å 323), Chile (n Å 198), Mexico (n Å 171), and Uruguay (n Å 169). Forty-five hospitals for confirmation and, regularly, a panel of five unknown isolates were submitted to the national reference laboratories for each contributed §10 isolates. Children õ24 months of age and those £6 months of age were the source of 65.3% and characterization, typing, and antimicrobial-resistance testing.
Standardized epidemiological information was collected on 27.5% of all isolates, respectively (figure 1). Among 1,622 isolates from children whose sex was reported, 58.4% were all children from whom S. pneumoniae was isolated. Data were analyzed with Epi-Info software, version 6.04b (Centers for from males. A primary diagnosis was reported for 1,621 patients. Pneumonia was identified in 817 patients (50.4%), menDisease Control and Prevention, Atlanta). The Mantel-Haenszel x 2 test was used to compare proportions. Odds ratios and ingitis in 528 (32.5%), sepsis or bacteremia without an infectious focus in 182 (11.2%), and other diagnoses in 94 (5.8%). 95% confidence intervals were determined with the Statcalc feature of Epi-Info.
S. pneumoniae was isolated from the blood of 856 patients (51.9%), the CSF of 448 (27.2%), the pleural fluid of 288 Three vaccine formulas were evaluated to determine the optimal number of capsular types that, if included in a vaccine (17.5%), and other sterile sites in 57 (3.5%). Eleven isolates from Uruguay and one isolate from Argentina designed for children, would provide uniform protection across the region. Types 6A and 6B were included together as group were not received by the respective national reference laboratories for serotyping and were not included in the analysis of 6 because of the high degree of cross-protective antibody in-/ 9c4e$$ju23 05-12-98 14:24:47 cidas UC: CID The development of the SIREVA network of laboratories represents a major effort by international, national, and local A second vaccine formula, incorporating the 12 most frequently isolated types, increased vaccine coverage significantly investigators to improve the regional infrastructure necessary for surveillance of infectious diseases [18 -22] . This study, throughout Latin America, from 71.7% to 84.6% (table 2) (OR Å 2.17; CI, 1.82 -2.58; P õ .001). The proportion of coverage based on the work of the SIREVA network, describes the first prospective multicountry surveillance for invasive S. pneumoby Vac12 in each of the countries, compared with coverage in Uruguay, was significantly less in both Argentina (83.7%; OR niae infections in Latin America. The study's main finding was the identification of types 14, Å 0.47; CI, 0.24 -0.85; P Å .01) and Mexico (72.5%; OR Å 0.22; CI, 0.10 -0.51; P Å .0006).
6, 5, 1, 23F, 19F, 19A, 7F, 9V, 18C, 3, 4, 16F, 9N, and 15B as the most prevalent in the region, accounting for 87.7% of The third vaccine, Vac15, was created by adding types 9N, 16F, and 15B. The region-wide coverage of Vac15 (87.7%) isolates obtained. We identified the most prevalent capsular types, taken exclusively from sterile sites in a population of was significantly higher than that of Vac12 (OR Å 1.38; CI, 1.13 -1.70; P Å .001). Mexico was the only country that continchildren, half of whom presented with lower respiratory tract infection. In addition, isolates were received from a large numued to have significantly fewer children covered by Vac15 than in Uruguay (OR Å 0.23; CI, 0.09 -0.55; P Å .001).
ber of hospitals throughout the region, the majority providing §10 isolates. The proportion of coverage by vaccine for all children õ2 years of age was compared with the coverage for children aged Such broad-based participation is likely to reflect the serotype distribution in the region. Although the order of most 2 -5 years (table 3 ). There were fewer study patients in Mexico Serotype prevalence data were used to compare coverage by all of the Americas. The finding of DSP among 25% of invasive pneumococcal three vaccine formulas. This analysis suggests that a 7-, 12-, or 15-valent vaccine covering the most prevalent regional types isolates is compatible with reports from other developing and some developed [33] countries; however, our observed rate of would achieve similar proportions of coverage in most of the participating countries. In Argentina, Brazil, Chile, and Colomhigh-level resistance (8.2%) was much greater [29, 30, 34] . This may reflect the presence of a highly resistant type (23F) bia, there were no statistically significant differences in the proportions of vaccine coverage by Vac7 or Vac15, in compariat two tertiary hospitals in Mexico City. In Mexico, 45.0% of isolates with DSP had high-level resistance, of which 55.6% son with coverage in Uruguay. A statistically significant difference in coverage between Uruguay and Argentina that was were of type 23F. When isolates from Mexico were excluded, the region-wide prevalence of isolates with DSP was 22.4%, observed with Vac12 disappeared with the Vac15 product after type 16F, particularly prevalent in Argentina, was included.
and the prevalence of high-level resistance was 6.7%. As has been identified in previous reports [35, 36] , the majority of Regional coverage improved significantly from 71.7% with Vac7 to 84.6% with Vac12. Although there was a further sigisolates (93%) with DSP were confined to groups 6, 9, 14, 19, and 23. nificant increase in region-wide coverage afforded by Vac15 (87.7%) in comparison with Vac12 coverage, vaccine develop-
The SIREVA network has provided the first multicountry prospective surveillance for invasive pneumococcal disease in ment costs and issues such as the total protein content of a 15-valent vaccine need to be considered before it can be deterthe developing world. It has established the most prevalent pneumococcal types and defined levels of DSP among children mined whether the marginal increase (3.1%) in coverage afforded by the 15-valent product is cost-beneficial.
with invasive pneumococcal disease in Latin America. It has also identified several vaccine formulas, based on prevalent The proportion of coverage in Mexico remained significantly lower than in other countries with all vaccine formulas. The regional types, that could achieve similar levels of coverage in most participating countries. type distribution of invasive pneumococci in Mexico determined in this study may reflect a selection bias. Eighty-nine Future surveillance programs will need to be designed to obtain better estimates of incidence and burden of illness repercent of Mexican isolates were from patients at two hospitals in urban Mexico City, a sample unlikely to reflect invasive lated to invasive pneumococcal disease. This information will be important to public health officials when evaluating the types of S. pneumoniae throughout the country. These results support the need for more comprehensive pneumococcal-dispotential impact of a protein-polysaccharide conjugate vaccine on respiratory disease in their respective jurisdictions. If pneuease surveillance in Mexico prior to evaluating the appropriateness of a commercial vaccine for local use.
mococcal conjugate-vaccine programs are implemented in Latin America, the SIREVA network will be used to monitor The importance of types 1 and 5 (10.7% and 10.6%, respectively) in Latin America have been confirmed in this and other changes in pneumococcal-type distribution and to assess the impact of immunization. studies [23 -25] , though they are relatively rare in the developed world [26, 27] . In contrast, many of the prevalent types identified in this study, including 14 
